C26 Stock Overview
Develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
CellaVision AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 17.56 |
| 52 Week High | SEK 25.95 |
| 52 Week Low | SEK 13.10 |
| Beta | 1.23 |
| 1 Month Change | 31.63% |
| 3 Month Change | -3.83% |
| 1 Year Change | -12.20% |
| 3 Year Change | -40.07% |
| 5 Year Change | -32.82% |
| Change since IPO | -31.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| C26 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -3.2% | -1.6% | 0.9% |
| 1Y | -12.2% | -12.3% | 13.2% |
Return vs Industry: C26 matched the German Medical Equipment industry which returned -12.9% over the past year.
Return vs Market: C26 underperformed the German Market which returned 13.2% over the past year.
Price Volatility
| C26 volatility | |
|---|---|
| C26 Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: C26's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: C26's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 228 | Simon Ostergaard | www.cellavision.com |
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers, instruments; and hardware products include in vitro diagnostics IVD for laboratories; as well as its portfolio includes smear makers, stainers, stains, and staining protocols; DIFF-Line is a hematology lab that handles a smaller amount daily blood samples and consists three instruments for smearing, staining, and analyzing peripheral blood smears CellaVision DC-1, RAL SmearBox, and RAL StainBox. It also provides CellaVision DC-1 for performing blood cell differentials; CellaVision DM1200 and CellaVision DM9600 are designed to automate and simplify the process of performing blood and body fluid differentials.
CellaVision AB (publ) Fundamentals Summary
| C26 fundamental statistics | |
|---|---|
| Market cap | €424.65m |
| Earnings (TTM) | €13.92m |
| Revenue (TTM) | €68.43m |
30.5x
P/E Ratio6.2x
P/S RatioIs C26 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C26 income statement (TTM) | |
|---|---|
| Revenue | SEK 747.94m |
| Cost of Revenue | SEK 235.72m |
| Gross Profit | SEK 512.22m |
| Other Expenses | SEK 360.10m |
| Earnings | SEK 152.12m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 18, 2025
| Earnings per share (EPS) | 6.38 |
| Gross Margin | 68.48% |
| Net Profit Margin | 20.34% |
| Debt/Equity Ratio | 2.7% |
How did C26 perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yield39%
Payout RatioDoes C26 pay a reliable dividends?
See C26 dividend history and benchmarks| CellaVision dividend dates | |
|---|---|
| Ex Dividend Date | May 07 2025 |
| Dividend Pay Date | May 13 2025 |
| Days until Ex dividend | 4 days |
| Days until Dividend pay date | 2 days |
Does C26 pay a reliable dividends?
See C26 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/09 19:41 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CellaVision AB (publ) is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sten Gustafsson | ABG Sundal Collier |
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Carl-Oscar Bredengen | Berenberg |